The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China

This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China

This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China

Inclusion Criteria:

• 1. Patients aged ≥18 years old
• 2. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria)；
• 3. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on Zanubrutinib;
• 4.Prior or current use of Zanubrutinib for ≥3 months
• 5.At least one follow-up was recorded during Zanubrutinib treatment

Exclusion Criteria:

-